Pre-made Nirsevimab benchmark antibody ( Whole mAb, anti-RSV therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nirsevimab is a passive immunisation, designed to provide RSV protection to all infants, whereby an antibody is given directly to an infant to help prevent RSV, unlike active immunisation, where a person's immune system is activated to prevent or fight infection through a vaccine.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-379-1mg	1mg	3090
GMP-Bios-ab-379-10mg	10mg	Inquiry
GMP-Bios-ab-379-100mg	100mg	Inquiry
GMP-Bios-ab-379-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody
INN Name	Nirsevimab
Target	RSV
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	5udc:HL:BC:EG
99% SI Structure	None
95-98% SI Structure	4jha:HL/4jhw:HL
Year Proposed	2018
Year Recommended	2019
Companies	AIMM Therapeutics;MedImmune
Conditions Approved	na
Conditions Active	Respiratory syncytial virus infections
Conditions Discontinued	na
Development Tech	na